KR101923364B1 - 아폽토시스­유도제의 염 및 결정형 - Google Patents

아폽토시스­유도제의 염 및 결정형 Download PDF

Info

Publication number
KR101923364B1
KR101923364B1 KR1020137016317A KR20137016317A KR101923364B1 KR 101923364 B1 KR101923364 B1 KR 101923364B1 KR 1020137016317 A KR1020137016317 A KR 1020137016317A KR 20137016317 A KR20137016317 A KR 20137016317A KR 101923364 B1 KR101923364 B1 KR 101923364B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
compound
group
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137016317A
Other languages
English (en)
Korean (ko)
Other versions
KR20140009265A (ko
Inventor
나다니엘 디. 캐트런
솽 천
위촨 궁
제프 지. 장
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101923364(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Publication of KR20140009265A publication Critical patent/KR20140009265A/ko
Application granted granted Critical
Publication of KR101923364B1 publication Critical patent/KR101923364B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020137016317A 2010-11-23 2011-11-21 아폽토시스­유도제의 염 및 결정형 Active KR101923364B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41665610P 2010-11-23 2010-11-23
US61/416,656 2010-11-23
PCT/US2011/061678 WO2012071336A1 (en) 2010-11-23 2011-11-21 Salts and crystalline forms of an apoptosis-inducing agent

Publications (2)

Publication Number Publication Date
KR20140009265A KR20140009265A (ko) 2014-01-22
KR101923364B1 true KR101923364B1 (ko) 2018-11-30

Family

ID=45094808

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137016317A Active KR101923364B1 (ko) 2010-11-23 2011-11-21 아폽토시스­유도제의 염 및 결정형

Country Status (27)

Country Link
US (10) US8722657B2 (enExample)
EP (1) EP2643322B1 (enExample)
JP (1) JP6141188B2 (enExample)
KR (1) KR101923364B1 (enExample)
CN (2) CN103328474A (enExample)
AU (1) AU2011332043C1 (enExample)
BR (1) BR112013012740A2 (enExample)
CA (1) CA2817629C (enExample)
CY (1) CY1119648T1 (enExample)
DK (1) DK2643322T3 (enExample)
ES (1) ES2644230T3 (enExample)
HR (1) HRP20171754T1 (enExample)
HU (1) HUE034804T2 (enExample)
IL (1) IL226489B (enExample)
LT (1) LT2643322T (enExample)
MX (1) MX343014B (enExample)
NO (1) NO2643322T3 (enExample)
NZ (1) NZ610151A (enExample)
PL (1) PL2643322T3 (enExample)
PT (1) PT2643322T (enExample)
RS (1) RS56697B1 (enExample)
RU (1) RU2628560C2 (enExample)
SG (1) SG190361A1 (enExample)
SI (1) SI2643322T1 (enExample)
TW (1) TWI526443B (enExample)
WO (1) WO2012071336A1 (enExample)
ZA (1) ZA201303586B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
ES2699205T3 (es) 2010-10-29 2019-02-07 Abbvie Inc Dispersiones sólidas que contienen un agente que induce la apoptosis
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ708508A (en) 2010-11-23 2016-06-24 Abbvie Bahamas Ltd Methods of treatment using selective bcl-2 inhibitors
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
CN111481552A (zh) 2012-09-07 2020-08-04 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
MX365343B (es) 2013-03-13 2019-05-30 Abbvie Inc Proceso para la fabricacion de un agente inductor de apoptosis.
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
LT3293176T (lt) 2013-10-22 2021-03-25 Chiesi Farmaceutici S.P.A. Pde4 inhibitoriaus kristalinė forma
JP6449293B2 (ja) 2013-12-06 2019-01-09 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
EP3169366A1 (en) 2014-07-14 2017-05-24 Gilead Sciences, Inc. Combinations for treating cancers
LT3179991T (lt) 2014-08-11 2021-11-10 Acerta Pharma B.V. Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
LT3319995T (lt) * 2015-07-07 2019-07-10 F. Hoffmann-La Roche Ag Sudėtinis gydymas anti-her-2 antikūno-vaisto konjugatu ir bcl-2 inhibitoriumi
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
WO2017079399A1 (en) 2015-11-03 2017-05-11 Genentech, Inc. Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
CN108367006B (zh) 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3468973A4 (en) * 2016-06-09 2020-02-26 Dr. Reddy's Laboratories Ltd. SOLID FORMS OF VENETOCLAX AND METHOD FOR PRODUCING VENETOCLAX
KR102429704B1 (ko) 2016-08-05 2022-08-04 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
US10759798B2 (en) * 2016-09-14 2020-09-01 Hangzhou Solipharma Co., Ltd. ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof
WO2018069941A2 (en) 2016-10-14 2018-04-19 Mylan Laboratories Limited Polymorphic forms of venetoclax
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
WO2018157803A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
WO2018225043A1 (en) * 2017-06-10 2018-12-13 Lupin Limited Solid state forms of an apoptosis-inducing agent and processes thereof
ES3028360T3 (en) * 2017-06-26 2025-06-19 Shenzhen Targetrx Inc Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
EP3672975B1 (en) 2017-08-23 2023-04-12 Guangzhou Lupeng Pharmaceutical Company Ltd. Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
WO2019135253A1 (en) * 2018-01-02 2019-07-11 Mylan Laboratories Limited Polymorphic forms of venetoclax
IT201800003284A1 (it) * 2018-03-05 2019-09-05 Olon Spa Forme cristalline di venetoclax
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
CN108997333A (zh) * 2018-07-04 2018-12-14 江苏中邦制药有限公司 一种b细胞淋巴瘤因子-2抑制剂abt-199的制备方法
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
EP3672594B1 (en) 2018-07-31 2021-09-29 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
WO2020041406A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
GB201911627D0 (en) * 2019-08-14 2019-09-25 Johnson Matthey Plc Polymorph of venetoclax and method for preparing the polymorph
US20230183236A1 (en) 2020-04-10 2023-06-15 Abbvie Inc. Crystalline forms of an apoptosis-inducing agent
BR112022021441A2 (pt) 2020-04-24 2022-12-13 Genentech Inc Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
US20230398110A1 (en) * 2020-08-21 2023-12-14 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
IL300996A (en) 2020-08-29 2023-04-01 argenx BV Treatment method for patients with reduced sensitivity to BCL-2 inhibitor
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
US20250195653A1 (en) 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184750A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
PT1019385E (pt) 1995-09-15 2004-06-30 Upjohn Co N-oxidos de aminoaril-oxazolidinona
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
KR100641802B1 (ko) 1999-12-28 2006-11-02 에자이 가부시키가이샤 술폰아미드 함유 복소환 화합물
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002098848A1 (en) * 2001-06-06 2002-12-12 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CA2833470C (en) 2002-02-26 2016-03-29 Astrazeneca Ab Processes for preparing form 1 zd1839 polymorph
CA2476587C (en) 2002-02-26 2010-05-04 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
EP1796642B1 (en) 2004-08-27 2008-05-21 Bayer Pharmaceuticals Corporation Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
KR101533268B1 (ko) 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
CN101218241B (zh) 2005-05-16 2011-02-16 Irm责任有限公司 用作蛋白激酶抑制剂的吡咯并吡啶衍生物
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
EP2195027A4 (en) 2007-10-01 2011-11-16 Univ Johns Hopkins METHOD FOR THE TREATMENT OF NEUROLOGICAL AUTOIMMUNE DISEASES WITH CYCLOPHOSPHAMID
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
MX2010005395A (es) 2007-11-16 2010-06-02 Abbott Lab Metodo para tratar artritis.
CN101939008A (zh) 2007-12-06 2011-01-05 雅培制药有限公司 用于治疗癌症的abt-263经口组合物
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
PL2346495T5 (pl) 2008-10-07 2024-06-10 Kudos Pharmaceuticals Limited Preparat farmaceutyczny 514
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP2376480B1 (en) 2008-12-05 2016-06-01 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
US20120094963A1 (en) 2008-12-23 2012-04-19 of Queen Elizabeth near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122019016429B1 (pt) 2009-05-26 2020-03-24 Abbvie Ireland Unlimited Company Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos
US20100302253A1 (en) 2009-05-29 2010-12-02 Microsoft Corporation Real time retargeting of skeletal data to game avatar
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
ES2699205T3 (es) 2010-10-29 2019-02-07 Abbvie Inc Dispersiones sólidas que contienen un agente que induce la apoptosis
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
AU2011332043C1 (en) * 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
NZ708508A (en) 2010-11-23 2016-06-24 Abbvie Bahamas Ltd Methods of treatment using selective bcl-2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184750A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
US20250340550A1 (en) 2025-11-06
CN107266435A (zh) 2017-10-20
DK2643322T3 (en) 2017-12-11
US20180065961A1 (en) 2018-03-08
US20200361932A1 (en) 2020-11-19
CN103328474A (zh) 2013-09-25
RU2013128612A (ru) 2014-12-27
HRP20171754T1 (hr) 2017-12-29
JP6141188B2 (ja) 2017-06-07
CA2817629A1 (en) 2012-05-31
EP2643322A1 (en) 2013-10-02
ES2644230T3 (es) 2017-11-28
US20230312566A1 (en) 2023-10-05
SI2643322T1 (en) 2018-01-31
CA2817629C (en) 2019-08-13
NO2643322T3 (enExample) 2018-01-27
MX343014B (es) 2016-10-20
IL226489A0 (en) 2013-07-31
US9840502B2 (en) 2017-12-12
SG190361A1 (en) 2013-06-28
IL226489B (en) 2018-02-28
AU2011332043B2 (en) 2016-08-11
US20190194196A1 (en) 2019-06-27
US20200255425A1 (en) 2020-08-13
AU2011332043C1 (en) 2016-11-10
TW201305154A (zh) 2013-02-01
BR112013012740A2 (pt) 2016-09-13
US20200231593A1 (en) 2020-07-23
JP2013543894A (ja) 2013-12-09
PL2643322T3 (pl) 2018-02-28
ZA201303586B (en) 2015-01-28
RS56697B1 (sr) 2018-03-30
WO2012071336A1 (en) 2012-05-31
US20160083384A1 (en) 2016-03-24
LT2643322T (lt) 2018-01-10
TWI526443B (zh) 2016-03-21
US8722657B2 (en) 2014-05-13
US9238649B2 (en) 2016-01-19
NZ610151A (en) 2015-06-26
HUE034804T2 (en) 2018-02-28
AU2011332043A1 (en) 2013-05-30
MX2013005851A (es) 2013-07-05
US20120157470A1 (en) 2012-06-21
US10730873B2 (en) 2020-08-04
US20140213596A1 (en) 2014-07-31
PT2643322T (pt) 2017-11-13
EP2643322B1 (en) 2017-08-30
KR20140009265A (ko) 2014-01-22
CY1119648T1 (el) 2018-04-04
RU2628560C2 (ru) 2017-08-18

Similar Documents

Publication Publication Date Title
KR101923364B1 (ko) 아폽토시스­유도제의 염 및 결정형
US8362014B2 (en) ABT-263 crystalline forms
CA3001880C (en) Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
EP3288931A1 (en) Certain protein kinase inhibitor
WO2017133663A1 (en) Phosphorus containing compounds as protein kinase inhibitors
US20230183236A1 (en) Crystalline forms of an apoptosis-inducing agent
HK1189233B (en) Salts and crystalline forms of an apoptosis-inducing agent
HK1189233A (en) Salts and crystalline forms of an apoptosis-inducing agent

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130621

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161121

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180102

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180702

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180102

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180702

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180326

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20161121

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20180903

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180801

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180702

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180326

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20161121

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20181123

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20181126

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220921

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee